First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean‐Charles Soria(Institut Gustave Roussy), Daniel S.W. Tan(Genome Institute of Singapore), Rita Chiari(Azienda Ospedaliera di Perugia), Yi‐Long Wu(Guangdong General Hospital), Luis Paz‐Ares(Universidad Complutense de Madrid), Juergen Wolf(University Hospital Cologne), Sarayut Lucien Geater(Songklanagarind Hospital), С. В. Орлов(First Pavlov State Medical University of St. Petersburg), Diego Cortinovis(Azienda Ospedaliera San Gerardo), Chong‐Jen Yu(National Taiwan University Hospital), Maximillian Hochmair(Otto Wagner Hospital), Alexis B. Cortot(Centre Hospitalier Universitaire de Lille), Chun‐Ming Tsai(Taipei Veterans General Hospital), Denis Moro‐Sibilot(Hôpital Albert Michallon), Rosario García Campelo(Universidade da Coruña), Tracey McCulloch(Novartis (United States)), Paramita Sen(Novartis (United States)), Margaret Dugan(Novartis (United States)), Serafino Pantano(Novartis (Switzerland)), Fabrice Branle(Novartis (Switzerland)), Cristian Massacesi(Novartis (Switzerland)), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo)
Cited by 1,148
Abstract
Related Papers
No related papers found
Powered by citation graph analysis